The oncogene role of METTL3 in AML has been well-established and its overexpression and oncogenic activity have subsequently been revealed in a variety of cancer types, including hepatocellular carcinoma, gastric cancer, and non-small cell lung cancer (14–17). The gene discussed is METTL3; the disease is gastric cancer.